Startups
Ventus Therapeutics has raised $140 million in a Series C financing round less than two years after launching to develop therapies aimed at diseases of the innate immune system.
The new funds will go toward advancing Congruence’s Revenir™ platform, a computational tool that models diseases that come from cellular proteins misfolding in order to understand them better.
San Diego-based Endeavor BioMedicines closed on a Series B financing worth $101 million.
TenSixteen Bio launched Thursday with a $40 million Series A financing round funded by Foresite Capital and GV, formerly Google Ventures.
Oxford BioMedica and Homology Medicines have formed a symbiotic partnership to launch a full scope AAV manufacturing and innovation business.
Led by Third Rock Ventures, the financing will support Septerna in tapping into new therapeutic areas for G protein-coupled receptor (GPCR) drug targets.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Hal Barron, the man who guided the reinvigoration of the pharmaceutical direction at GSK, is departing the company to be the CEO of Altos Labs.
The company’s co-Founder, President and CEO Dr. P. Peter Ghoroghchian, took time to discuss the company and the financing round with BioSpace.
Funds are always flowing in the life science industry. Here’s where the money’s headed this week.
PRESS RELEASES